p-cresylsulfate and indoxyl sulfate level at different stages of chronic kidney disease

Journal of Clinical Laboratory Analysis

Volumn 25, Issue 3, 2011, Pages 191-197

  Lin, Cheng Jui ^a,b,c   Chen, Han Hsiang ^a,b   Pan, Chi Feng ^a,d,e   Chuang, Chih Kuang ^a   Wang, Tuen Jen ^c   Sun, Fang Ju ^a,b   Wu, Chih Jen ^a,b,f  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c YUANPEI UNIVERSITY   (Taiwan)

^d FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^e NATIONAL TAIPEI UNIVERSITY OF TECHNOLOGY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Chronic kidney disease; Indoxyl sulfate; p cresylsulfate; Protein bound uremic toxin

Indexed keywords

CREATININE; INDICAN; PARA CRESYL SULFATE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CHRONIC KIDNEY DISEASE; CORRELATION ANALYSIS; CREATININE BLOOD LEVEL; DISEASE SEVERITY; FEMALE; HEMODIALYSIS PATIENT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE;

COHORT STUDIES; CRESOLS; FEMALE; HUMANS; INDICAN; KIDNEY FAILURE, CHRONIC; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS;

EID: 79955883106     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20456     Document Type: Article

References (27)

1. Vanholder R, De Smet R. Pathophysiologic effects of uremic retention solutes. J Am Soc Nephrol 1999;10:1815-1823.
2. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: Classification, concentration, and interindividual variability. Kidney Int 2003;63:1934-1943.
3. Niwa T, Nomura T, Sugiyama S, et al. The protein metabolite hypothesis, a model for the progression of renal failure: An oral sorbent lowers indoxyl sulfate levels in undialyzed uremic patients. Kidney Int 1997;52:S23-S28.
4. Dou L, Bertrand E, Cerini C, et al. The uremic solutes p-cresol and indoxyl sulfate inhibit endothelial proliferation and wound repair. Kidney Int 2004;65:442-451.
5. Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol 2007;27:30-35.
6. De Loor H, Bammens B, Evenepoel P, et al. Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum. Clin Chem 2005;51:1535-1538.
7. Martinez AW, Recht NS, Hostetter TH, et al. Removal of P-cresol sulfate by hemodialysis. J Am Soc Nephrol 2005;16:3430-3436.
8. Wratten ML, Tetta C, De Smet R, et al. Uremic ultrafiltrate inhibits platelet-activating factor synthesis. Blood Purif 1999;17:134-141.
9. Vanholder R, De Smet R, Waterloos MA, et al. Mechanisms of uremic inhibition of phagocyte reactive species production: characterization of the role of p-cresol. Kidney Int 1995;47:510-517.
10. Dou L, Cerini C, Brunet P, et al. P-cresol, a uremic toxin, decreases endothelial cell response to inflammatory cytokines. Kidney Int 2002;62:1999-2009.
11. De Smet R, Van Kaer J, Van Vlem B, et al. Toxicity of free p-cresol: A prospective and cross-sectional analysis. Clin Chem 2003;49:470-478.
12. Schepers E, Meert N, Glorieux G, et al. P-cresylsulphate, the main in vivo metabolite of p-cresol, activates leucocyte free radical production. Nephrol Dial Transplant 2007;22:592-596.
13. Bammens B, Evenepoel P, Keuleers H, et al. Free serum concentrations of the proteinbound retention solute p-cresol predict mortality in hemodialysis patients. Kidney Int 2006;69:1081-1087.
14. Meijers BK, Bammens B, De Moor B, et al. Free p-cresol is associated with cardiovascular disease in hemodialysis patients. Kidney Int 2008;73:1174-1180.
15. Lin CJ, Wu CJ, Pan CF, et al. Serum protein-bound uremic toxins and clinical outcomes in hemodialysis patients. Nephrol Dial Transplant 2010;25:3693-3700.
16. Barreto FC, Barreto DV, Liabeuf S, et al. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 2009;4:1551-1558.
17. Liabeuf S, Barreto DV, Barreto FC, et al. Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 2010;25:1183-1191.
18. Bammens B, Evenepoel P, Verbeke K, et al. Removal of the protein-bound solute p-cresol by convective transport: a randomized crossover study. Am J Kidney Dis 2004;44:2278-2285.
19. Krieter DH, Hackl A, Rodriguez A, et al. Protein-bound uraemic toxin removal in haemodialysis and post-dilution haemodiafiltration. Nephrol Dial Transplant 2010;25:212-218.
20. Bammens B, Evenepoel P, Verbeke K, et al. Time profiles of peritoneal and renal clearances of different uremic solutes in incident peritoneal dialysis patients. Am J Kidney Dis 2005;46:512-519.
21. Lin CJ, Wu CJ, Pan CF, et al. Serum concentration of p-cresol and indoxyl sulfate in elderly hemodialysis patients. Int J Gerontol 2010; in press
22. De Preter V, Vanhoutte T, Huys G, et al. Effects of Lactobacillus casei Shirota, Bifidobacterium breve, and oligofructose-enriched inulin on colonic nitrogen-protein metabolism in healthy humans. Am J Physiol Gastrointest Liver Physiol 2007;292:G358-G368.
23. Meijers BK, De Preter V, Verbeke K, et al. P-Cresyl sulfate serum concentrations in haemodialysis patients are reduced by the prebiotic oligofructose-enriched inulin. Nephrol Dial Transplant 2010;25:219-224.
24. Fujii H, Nishijima F, Goto S, et al. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress. Nephrol Dial Transplant 2009;24:2089-2095.
25. De Smet R, Thermote F, Lamiere N. Sevelamer hydrochloride adsorbs the uremic compound indoxyl sulfate [abstract]. J Am Soc Nephrol 2003;14:206A.
26. Phan O, Ivanovski O, Nguyen-Khoa T, et al. Sevelamer prevents uremiaenhanced atherosclerosis progression in apolipoprotein E-deficient mice. Circulation 2005;112:2875-2882.
27. Meijers BK, De Loor H, Bammens B, et al. P-Cresyl sulfate and indoxyl sulfate in hemodialysis patients. Clin J Am Soc Nephrol 2009;4:1932-1938.